Samuel L. Volchenboum to Child
This is a "connection" page, showing publications Samuel L. Volchenboum has written about Child.
Connection Strength
1.146
-
GDPR and data sharing: the Pediatric Cancer Data Commons experience. Lancet Oncol. 2024 Jun; 25(6):e227.
Score: 0.105
-
Targeted Enrollment in Pediatric Oncology Trials: A Vision for Just-in-Time Matching. JCO Oncol Pract. 2024 May; 20(5):603-606.
Score: 0.103
-
Using A Standardized Nomenclature to Semantically Map Oncology-Related Concepts from Common Data Models to a Pediatric Cancer Data Model. AMIA Annu Symp Proc. 2023; 2023:874-883.
Score: 0.102
-
Automated Matching of Patients to Clinical Trials: A Patient-Centric Natural Language Processing Approach for Pediatric Leukemia. JCO Clin Cancer Inform. 2023 07; 7:e2300009.
Score: 0.098
-
Using big data in pediatric oncology: Current applications and future directions. Semin Oncol. 2020 02; 47(1):56-64.
Score: 0.078
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
Score: 0.071
-
Data Commons to Support Pediatric Cancer Research. Am Soc Clin Oncol Educ Book. 2017; 37:746-752.
Score: 0.063
-
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9.
Score: 0.037
-
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter study. Pediatr Blood Cancer. 2024 Oct; 71(10):e31218.
Score: 0.026
-
Making sense of artificial intelligence and large language models-including ChatGPT-in pediatric hematology/oncology. Pediatr Blood Cancer. 2024 Sep; 71(9):e31143.
Score: 0.026
-
Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL). J Natl Cancer Inst. 2024 May 08; 116(5):642-646.
Score: 0.026
-
Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module. JCO Clin Cancer Inform. 2024 May; 8:e2400009.
Score: 0.026
-
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. J Clin Oncol. 2023 08 20; 41(24):4045-4053.
Score: 0.024
-
Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Br J Cancer. 2022 11; 127(9):1577-1583.
Score: 0.023
-
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). Pediatr Blood Cancer. 2022 11; 69(11):e29924.
Score: 0.023
-
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
Score: 0.023
-
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589.
Score: 0.023
-
Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. JCO Glob Oncol. 2022 02; 8:e2100266.
Score: 0.022
-
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5.
Score: 0.022
-
Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review. JCO Clin Cancer Inform. 2021 12; 5:1208-1219.
Score: 0.022
-
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clin Cancer Inform. 2021 09; 5:1034-1043.
Score: 0.022
-
Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. JCO Clin Cancer Inform. 2021 08; 5:881-896.
Score: 0.022
-
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
Score: 0.021
-
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905.
Score: 0.020
-
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
Score: 0.020
-
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
Score: 0.016
-
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10.
Score: 0.015
-
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
Score: 0.015
-
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol. 2016 Mar 01; 34(7):740-6.
Score: 0.015
-
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
Score: 0.014
-
Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
Score: 0.013
-
3 + 3 not equal to (Rolling) 6. J Clin Oncol. 2008 Jan 10; 26(2):170-1.
Score: 0.008